https://www.selleckchem.com/products/Y-27632.html
Based on meta-analysis of RCTs, the use of ivermectin was not associated with reduction in time to viral clearance, duration of hospitalization, incidence of mortality and incidence of mechanical ventilation. Ivermectin did not significantly increase incidence of adverse events. Meta-analysis of OSs agrees with findings from RCT studies. Based on very low to moderate quality of evidence, ivermectin was not efficacious at managing COVID-19. It's safety profile permits its use in trial settings to further clarify its role in COVID-19 trea